Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: Evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study

Arie Levine, Dan Turner, Tamar Pfeffer Gik, Jorge Amil Dias, G. Verès, Ron Shaoul, Annamaria Staiano, Johanna Escher, Kaija Leena Kolho, Anders Paerregaard, Javier Martin De Carpi, Gigi Veereman Wauters, Sibylle Koletzko, Orit Shevah, Lenne Finnby, Malgorzata Sladek

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Robust evaluation of induction therapies using both clinical and inflammatory outcomes in pediatric Crohn's disease (CD) are sparse. We attempted to evaluate clinical, inflammatory, and composite outcomes of induction of remission therapies (normal C reactive protein [CRP] remission) in a large pediatric prospective multicenter study. Methods: Patients enrolled at diagnosis into the growth relapse and outcomes with therapy in Crohn's disease study were evaluated for disease activity, CRP, and fecal calprotectin at 8, 12 and 52 weeks after starting treatment. The primary endpoint was week-12 steroid-free remission defined by pediatric Crohn's disease activity index and CRP

Original languageEnglish
Pages (from-to)278-285
Number of pages8
JournalInflammatory Bowel Diseases
Volume20
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Remission Induction
Crohn Disease
C-Reactive Protein
Recurrence
Growth
Leukocyte L1 Antigen Complex
Therapeutics
Multicenter Studies
Steroids
Prospective Studies
Pediatrics
Pediatric Crohn's disease

Keywords

  • Biomarkers
  • C reactive protein
  • Crohn's disease
  • Exclusive enteral nutrition
  • Outcomes
  • Relapse
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease : Evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. / Levine, Arie; Turner, Dan; Gik, Tamar Pfeffer; Dias, Jorge Amil; Verès, G.; Shaoul, Ron; Staiano, Annamaria; Escher, Johanna; Kolho, Kaija Leena; Paerregaard, Anders; De Carpi, Javier Martin; Wauters, Gigi Veereman; Koletzko, Sibylle; Shevah, Orit; Finnby, Lenne; Sladek, Malgorzata.

In: Inflammatory Bowel Diseases, Vol. 20, No. 2, 02.2014, p. 278-285.

Research output: Contribution to journalArticle

Levine, A, Turner, D, Gik, TP, Dias, JA, Verès, G, Shaoul, R, Staiano, A, Escher, J, Kolho, KL, Paerregaard, A, De Carpi, JM, Wauters, GV, Koletzko, S, Shevah, O, Finnby, L & Sladek, M 2014, 'Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: Evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study', Inflammatory Bowel Diseases, vol. 20, no. 2, pp. 278-285. https://doi.org/10.1097/01.MIB.0000437735.11953.68
Levine, Arie ; Turner, Dan ; Gik, Tamar Pfeffer ; Dias, Jorge Amil ; Verès, G. ; Shaoul, Ron ; Staiano, Annamaria ; Escher, Johanna ; Kolho, Kaija Leena ; Paerregaard, Anders ; De Carpi, Javier Martin ; Wauters, Gigi Veereman ; Koletzko, Sibylle ; Shevah, Orit ; Finnby, Lenne ; Sladek, Malgorzata. / Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease : Evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study. In: Inflammatory Bowel Diseases. 2014 ; Vol. 20, No. 2. pp. 278-285.
@article{81dbf0da674e4b68b004339bbe9f9961,
title = "Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: Evaluation of the porto IBD group {"}growth relapse and outcomes with therapy{"} (GROWTH CD) study",
abstract = "Background: Robust evaluation of induction therapies using both clinical and inflammatory outcomes in pediatric Crohn's disease (CD) are sparse. We attempted to evaluate clinical, inflammatory, and composite outcomes of induction of remission therapies (normal C reactive protein [CRP] remission) in a large pediatric prospective multicenter study. Methods: Patients enrolled at diagnosis into the growth relapse and outcomes with therapy in Crohn's disease study were evaluated for disease activity, CRP, and fecal calprotectin at 8, 12 and 52 weeks after starting treatment. The primary endpoint was week-12 steroid-free remission defined by pediatric Crohn's disease activity index and CRP",
keywords = "Biomarkers, C reactive protein, Crohn's disease, Exclusive enteral nutrition, Outcomes, Relapse, Treatment",
author = "Arie Levine and Dan Turner and Gik, {Tamar Pfeffer} and Dias, {Jorge Amil} and G. Ver{\`e}s and Ron Shaoul and Annamaria Staiano and Johanna Escher and Kolho, {Kaija Leena} and Anders Paerregaard and {De Carpi}, {Javier Martin} and Wauters, {Gigi Veereman} and Sibylle Koletzko and Orit Shevah and Lenne Finnby and Malgorzata Sladek",
year = "2014",
month = "2",
doi = "10.1097/01.MIB.0000437735.11953.68",
language = "English",
volume = "20",
pages = "278--285",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease

T2 - Evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study

AU - Levine, Arie

AU - Turner, Dan

AU - Gik, Tamar Pfeffer

AU - Dias, Jorge Amil

AU - Verès, G.

AU - Shaoul, Ron

AU - Staiano, Annamaria

AU - Escher, Johanna

AU - Kolho, Kaija Leena

AU - Paerregaard, Anders

AU - De Carpi, Javier Martin

AU - Wauters, Gigi Veereman

AU - Koletzko, Sibylle

AU - Shevah, Orit

AU - Finnby, Lenne

AU - Sladek, Malgorzata

PY - 2014/2

Y1 - 2014/2

N2 - Background: Robust evaluation of induction therapies using both clinical and inflammatory outcomes in pediatric Crohn's disease (CD) are sparse. We attempted to evaluate clinical, inflammatory, and composite outcomes of induction of remission therapies (normal C reactive protein [CRP] remission) in a large pediatric prospective multicenter study. Methods: Patients enrolled at diagnosis into the growth relapse and outcomes with therapy in Crohn's disease study were evaluated for disease activity, CRP, and fecal calprotectin at 8, 12 and 52 weeks after starting treatment. The primary endpoint was week-12 steroid-free remission defined by pediatric Crohn's disease activity index and CRP

AB - Background: Robust evaluation of induction therapies using both clinical and inflammatory outcomes in pediatric Crohn's disease (CD) are sparse. We attempted to evaluate clinical, inflammatory, and composite outcomes of induction of remission therapies (normal C reactive protein [CRP] remission) in a large pediatric prospective multicenter study. Methods: Patients enrolled at diagnosis into the growth relapse and outcomes with therapy in Crohn's disease study were evaluated for disease activity, CRP, and fecal calprotectin at 8, 12 and 52 weeks after starting treatment. The primary endpoint was week-12 steroid-free remission defined by pediatric Crohn's disease activity index and CRP

KW - Biomarkers

KW - C reactive protein

KW - Crohn's disease

KW - Exclusive enteral nutrition

KW - Outcomes

KW - Relapse

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84893761513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893761513&partnerID=8YFLogxK

U2 - 10.1097/01.MIB.0000437735.11953.68

DO - 10.1097/01.MIB.0000437735.11953.68

M3 - Article

C2 - 24390062

AN - SCOPUS:84893761513

VL - 20

SP - 278

EP - 285

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 2

ER -